Masimo (MASI) Competitors $168.03 -3.85 (-2.24%) Closing price 04:00 PM EasternExtended Trading$168.00 -0.03 (-0.02%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MASI vs. RMD, DXCM, STE, PODD, BAX, HOLX, GMED, TFX, ITGR, and ATECShould you be buying Masimo stock or one of its competitors? The main competitors of Masimo include ResMed (RMD), DexCom (DXCM), STERIS (STE), Insulet (PODD), Baxter International (BAX), Hologic (HOLX), Globus Medical (GMED), Teleflex (TFX), Integer (ITGR), and Alphatec (ATEC). These companies are all part of the "health care equipment" industry. Masimo vs. ResMed DexCom STERIS Insulet Baxter International Hologic Globus Medical Teleflex Integer Alphatec Masimo (NASDAQ:MASI) and ResMed (NYSE:RMD) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations. Does the media refer more to MASI or RMD? In the previous week, ResMed had 7 more articles in the media than Masimo. MarketBeat recorded 13 mentions for ResMed and 6 mentions for Masimo. ResMed's average media sentiment score of 1.10 beat Masimo's score of 0.69 indicating that ResMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Masimo 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive ResMed 8 Very Positive mention(s) 4 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in MASI or RMD? 86.0% of Masimo shares are held by institutional investors. Comparatively, 55.0% of ResMed shares are held by institutional investors. 9.7% of Masimo shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts recommend MASI or RMD? Masimo currently has a consensus price target of $191.60, indicating a potential upside of 11.47%. ResMed has a consensus price target of $259.33, indicating a potential upside of 3.31%. Given Masimo's stronger consensus rating and higher probable upside, research analysts plainly believe Masimo is more favorable than ResMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Masimo 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83ResMed 1 Sell rating(s) 5 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.60 Which has more volatility & risk, MASI or RMD? Masimo has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, ResMed has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Which has higher valuation and earnings, MASI or RMD? ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMasimo$2.13B4.38$81.50M-$9.17-18.74ResMed$5.02B7.33$1.02B$8.9128.17 Is MASI or RMD more profitable? ResMed has a net margin of 25.34% compared to Masimo's net margin of 3.85%. ResMed's return on equity of 26.17% beat Masimo's return on equity.Company Net Margins Return on Equity Return on Assets Masimo3.85% 14.98% 6.95% ResMed 25.34%26.17%18.60% Does the MarketBeat Community believe in MASI or RMD? Masimo received 30 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 63.76% of users gave Masimo an outperform vote while only 52.58% of users gave ResMed an outperform vote. CompanyUnderperformOutperformMasimoOutperform Votes46863.76% Underperform Votes26636.24% ResMedOutperform Votes43852.58% Underperform Votes39547.42% SummaryResMed beats Masimo on 11 of the 19 factors compared between the two stocks. Get Masimo News Delivered to You Automatically Sign up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MASI vs. The Competition Export to ExcelMetricMasimoElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.32B$3.36B$5.50B$8.63BDividend YieldN/A1.77%5.27%4.19%P/E Ratio118.5418.4527.1720.15Price / Sales4.38194.88408.68161.57Price / Cash30.7444.0938.2534.64Price / Book6.663.936.954.72Net Income$81.50M$94.03M$3.23B$248.00M7 Day Performance4.91%1.26%5.19%3.71%1 Month Performance9.35%12.85%13.94%10.34%1 Year Performance35.17%-5.76%32.28%15.16% Masimo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MASIMasimo4.0141 of 5 stars$168.03-2.2%$191.60+14.0%+37.0%$9.11B$2.13B115.886,200RMDResMed4.0591 of 5 stars$243.90-0.4%$259.33+6.3%+19.0%$35.76B$5.02B28.808,160Positive NewsDXCMDexCom4.7689 of 5 stars$85.51-0.3%$98.32+15.0%-26.0%$33.53B$4.15B59.807,600Positive NewsSTESTERIS4.6061 of 5 stars$241.87-1.4%$263.83+9.1%+7.0%$23.76B$5.46B51.3516,000Positive NewsAnalyst RevisionPODDInsulet4.1147 of 5 stars$325.000.0%$318.41-2.0%+59.7%$22.87B$2.20B56.132,600Positive NewsBAXBaxter International4.6418 of 5 stars$29.54-3.1%$37.25+26.1%-6.9%$15.16B$10.77B-23.0860,000Options VolumeHOLXHologic4.8054 of 5 stars$62.01-0.3%$77.42+24.8%-13.3%$13.82B$4.03B19.566,940Positive NewsGMEDGlobus Medical4.7415 of 5 stars$58.94-0.4%$94.00+59.5%-7.3%$7.98B$2.51B78.592,600TFXTeleflex4.8754 of 5 stars$119.65-2.1%$164.63+37.6%-42.0%$5.29B$3.01B23.7915,500ITGRInteger3.0692 of 5 stars$117.69-0.9%$145.00+23.2%+0.8%$4.11B$1.75B35.0310,000ATECAlphatec4.0501 of 5 stars$12.30-1.0%$17.89+45.4%+15.8%$1.80B$642.27M-9.61700 Related Companies and Tools Related Companies ResMed Alternatives DexCom Alternatives STERIS Alternatives Insulet Alternatives Baxter International Alternatives Hologic Alternatives Globus Medical Alternatives Teleflex Alternatives Integer Alternatives Alphatec Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MASI) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Masimo Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Masimo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
